CTRI/2015/05/005806
Completed
Phase 4
A Multi-centric, Double blind, Placebo controlled, Randomized, observational study to evaluate the Efficacy and Safety of Carica Papaya Leaf Extract, as empirical therapy for thrombocytopenia associated with dengue feverSafety of Carica Papaya Leaf Extract, as empirical therapy for thrombocytopenia associated with dengue fever
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Dengue patients
- Sponsor
- Micro Labs Ltd
- Enrollment
- 300
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Subjects must sign with date an Informed Consent (ICF) prior to any evaluation and participation in the trial,
- •2\.Male and female patients above 18 years and below 60 years old,
- •3\.Patients who were confirmed to have DF or DHF grade I and II,
- •4\.Patients with a platelet count of less than 100,000/μL,
- •5\.Patients with a baseline alanine transaminase (ALT) level of not more than 3 times of the upper limit of the normal range (not more than 165U/L),
Exclusion Criteria
- •Pregnant or lactating women,
- •2\.Patients with Dengue hemorrhagic fever grade III and IV,
- •3\.Patients with platelet count less than 20000/microlitre
- •4\.Patients with thrombocytopenia presenting with active bleeding
- •5\.Patients who have received blood or blood products transfusion during the current illness or during past one week,
- •6\.Patients with thrombocytopenia Purpura (ITP), Leukemia, Hemophilia or bleeding diathesis
- •7\.Patients who developed Hepatitis with a serum ALT level 3 times higher than the upper limit of the normal range ( \>165â??U/L).
- •8\.Impaired renal function with serum creatinine \>1\.5 mg/dl(males) and \>1\.4 mg/dl(females)
- •9\.Participation in another trial with another investigational drug within 1 month prior to informed consent.
- •10\.The presence of any other condition that leads the investigator to conclude that the patient is inappropriate for inclusion in the clinical study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
Benefit of carica papaya leaf extract in cancer patientsHealth Condition 1: null- CancerCTRI/2017/07/008954Katra Phytochem Pvt ltd
Completed
Phase 4
Clinical trial for A life saving measure for Dengue patients :Carica Papaya Leaf ExtractCTRI/2018/07/014988Mi Lab LifeSciencesP Limited
Recruiting
Phase 3
Evaluation of Clinical Endpoints of Two Sucralfate suspension, 1g/10mCTRI/2013/04/003538HiTech Pharmacal Co Inc575
Recruiting
Phase 2
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes TherapiesHealth Condition 1: null- Diabetes Mellitus Type 2Impaired Glucose ToleranceCTRI/2010/091/000151ovartis Healthcare Private Limited244
Active, not recruiting
Not Applicable
A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Safety Study ofPulmonary Function in Patients with Reduced Lung Function Treated with BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex for Focal Upper LimbSpasticity Due to Upper Motor Neuron SyndromeEUCTR2005-004834-42-HUAllergan150